How India Exports Sunitinib to the World

In the United States, sunitinib is approved for the treatment of gastrointestinal stromal tumors (GIST), advanced renal cell carcinoma (RCC), and pancreatic neuroendocrine tumors (pNET). The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for sunitinib, indicating a competitive generic market. Notably, the presence of 114 active Indian exporters underscores India's significant role in supplying sunitinib to the U.S. market.

The regulatory pathway for sunitinib in the U.S. involves demonstrating bioequivalence to the reference listed drug, Sutent. As of March 2026, there are no active import alerts related to sunitinib, suggesting compliance with FDA standards. The substantial export volume to the U.S. (38.4% of total exports) reflects robust demand and regulatory acceptance.

In the European Union, sunitinib received conditional marketing authorization in July 2006, which was converted to full approval in January 2007. The European Medicines Agency (EMA) has approved both the originator product, Sutent, and generic versions like Sunitinib Accord, which received marketing authorization on February 11, 2021. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, ensuring consistent regulatory requirements across these markets.

Manufacturers exporting to the EU and UK must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA and MHRA. This includes regular inspections and adherence to quality assurance protocols to ensure product safety and efficacy.

Sunitinib is included in the World Health Organization's Model List of Essential Medicines, highlighting its importance in treating specific cancers. The drug is subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, sunitinib is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing under the Drug Price Control Order (DPCO). Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) to ensure compliance with export regulations.

The primary patents for sunitinib have expired, leading to increased generic competition. This has resulted in a diversified market with multiple manufacturers supplying sunitinib globally, contributing to the significant export figures from India.

In June 2025, the EMA approved a new generic version of sunitinib, further increasing market competition and potentially impacting pricing dynamics.

In September 2025, the NPPA revised the ceiling price for sunitinib, reflecting changes in production costs and market conditions.

In December 2025, the FDA issued updated guidance on bioequivalence requirements for sunitinib, aiming to streamline the approval process for generic manufacturers.

In February 2026, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of sunitinib for the treatment of specific cancers.

In March 2026, the CDSCO implemented stricter quality control measures for the export of oncology drugs, including sunitinib, to enhance global compliance and safety standards.

These developments underscore the dynamic regulatory landscape for sunitinib, with ongoing efforts to balance accessibility, affordability, and quality in the global pharmaceutical market.

India's pharmaceutical industry, renowned as the "pharmacy of the world," heavily relies on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of India's APIs are imported from China, underscoring a significant dependency on Chinese suppliers for essential raw materials. This reliance exposes the supply chain to vulnerabilities, particularly during geopolitical tensions or trade disruptions.

To mitigate this dependency, the Indian government initiated the Production Linked Incentive (PLI) scheme in October 2024, aiming to bolster domestic production of critical APIs and KSMs. Two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-Aminopenicillanic acid (6-APA), which are vital for common antibiotics. These efforts are projected to reduce India's import dependence on key pharmaceutical ingredients by half.

Our proprietary trade data from 2022 to 2026 reveals a high supplier concentration for Sunitinib exports from India. The top five exporters account for 90.1% of the total export value, with SUN PHARMACEUTICAL INDUSTRIES LIMITED alone contributing 76.2% ($48.4 million). This significant concentration poses a single-source risk, as any disruption in operations or compliance issues within these key suppliers could severely impact the global supply of Sunitinib.

The PLI scheme, launched in October 2024, aims to diversify and strengthen the supplier base by incentivizing domestic production of APIs and KSMs. While this initiative is a positive step, its impact on reducing supplier concentration for specific drugs like Sunitinib remains to be fully realized.

Recent geopolitical events have significantly disrupted global supply chains. In February 2026, the closure of the Strait of Hormuz following military conflicts led to substantial delays in the transportation of pharmaceuticals and other goods. Approximately 3,200 ships were stalled within the Persian Gulf, causing worldwide logistical shortages and rising prices. Such disruptions highlight the vulnerability of pharmaceutical supply chains to geopolitical tensions.

Additionally, the U.S. Food and Drug Administration (FDA) has been actively monitoring and addressing supply chain challenges. The FDA's role includes working with industry partners to identify and mitigate shortages of FDA-regulated products, emphasizing the importance of a resilient supply chain.

• Diversify Supplier Base: Encourage the development of additional domestic manufacturers for Sunitinib to reduce reliance on a limited number of suppliers.

• Strengthen Domestic API Production: Accelerate the implementation of the PLI scheme to enhance local production of critical APIs and KSMs, thereby reducing dependency on imports.

• Enhance Supply Chain Transparency: Implement robust tracking systems to monitor the sourcing and movement of raw materials and finished products, enabling quicker responses to disruptions.

• Develop Contingency Plans: Establish strategic reserves of essential APIs and finished drugs to buffer against supply chain interruptions.

• Engage in International Collaboration: Work with global regulatory bodies and trade partners to develop coordinated responses to supply chain challenges and ensure the continuous availability of critical medications.

RISK_LEVEL: HIGH